Healthcare giant Gilead Sciences, Inc. (NASDAQ:GILD) is gearing up for another quarterly report after the closing bell on Wednesday.
Mizuho analyst Salim Syed initiates coverage on Gilead Sciences, Inc. (NASDAQ:GILD) with a Buy rating and an $88 price target, which represents just under a …
